[
  {
    "ts": "2026-01-20T16:04:00+00:00",
    "headline": "Organon Secures FDA Approval Extending NEXPLANON Use to Five Years",
    "summary": "OGN wins FDA approval to extend NEXPLANON use to five years, backed by trials showing no pregnancies and strong efficacy across body weights.",
    "url": "https://finance.yahoo.com/news/organon-secures-fda-approval-extending-160400612.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "3ea67fbd-5d37-32cc-8837-cd5ef1bb0a58",
      "content": {
        "id": "3ea67fbd-5d37-32cc-8837-cd5ef1bb0a58",
        "contentType": "STORY",
        "title": "Organon Secures FDA Approval Extending NEXPLANON Use to Five Years",
        "description": "",
        "summary": "OGN wins FDA approval to extend NEXPLANON use to five years, backed by trials showing no pregnancies and strong efficacy across body weights.",
        "pubDate": "2026-01-20T16:04:00Z",
        "displayTime": "2026-01-20T16:04:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/4658663242c3a61dee3fef55a1bf4887",
          "originalWidth": 620,
          "originalHeight": 413,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rbSgl25Zi2GiiDMk0hXrSg--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4658663242c3a61dee3fef55a1bf4887.cf.webp",
              "width": 620,
              "height": 413,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NAknAcj0fz57CxpyeoYG3A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4658663242c3a61dee3fef55a1bf4887.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/organon-secures-fda-approval-extending-160400612.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/organon-secures-fda-approval-extending-160400612.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "OGN"
            },
            {
              "symbol": "CRL"
            },
            {
              "symbol": "MD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-20T16:00:00+00:00",
    "headline": "Here's Why You Should Retain CLOV Stock in Your Portfolio for Now",
    "summary": "Clover Health shows strong membership growth, rising revenues and sustained EBITDA gains from Clover Assistant, though near-term margin pressure remains a risk.",
    "url": "https://finance.yahoo.com/news/heres-why-retain-clov-stock-160000335.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "4f43bf31-8838-3207-85bc-9467a8fe4ff6",
      "content": {
        "id": "4f43bf31-8838-3207-85bc-9467a8fe4ff6",
        "contentType": "STORY",
        "title": "Here's Why You Should Retain CLOV Stock in Your Portfolio for Now",
        "description": "",
        "summary": "Clover Health shows strong membership growth, rising revenues and sustained EBITDA gains from Clover Assistant, though near-term margin pressure remains a risk.",
        "pubDate": "2026-01-20T16:00:00Z",
        "displayTime": "2026-01-20T16:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/6e7a581172a57923b1e9381146e28fb5",
          "originalWidth": 620,
          "originalHeight": 413,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4mGL7zFW4ML.rueGFlAaKQ--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6e7a581172a57923b1e9381146e28fb5.cf.webp",
              "width": 620,
              "height": 413,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/i_0DPni3TtRoN19G7I0YLA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6e7a581172a57923b1e9381146e28fb5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/heres-why-retain-clov-stock-160000335.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/heres-why-retain-clov-stock-160000335.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CLOV"
            },
            {
              "symbol": "CRL"
            },
            {
              "symbol": "MD"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]